The Real Number of People With Parkinson's Disease (It's Rising)

Approximately 1 million people in the United States and over 10 million people worldwide are living with Parkinson’s disease as of 2026, according to the Parkinson’s Foundation. This progressive neurodegenerative disorder primarily affects movement, causing tremors, stiffness, and balance problems. The condition is the second most common neurodegenerative disease after Alzheimer’s, with about 60,000 new cases diagnosed annually in the US. Prevalence increases with age, affecting approximately 1-2% of people over age 65. Parkinson’s disease is the fastest-growing neurological disorder globally in terms of disability, driven by aging populations and improved diagnostic capabilities.

Last updated: July 2026 — Updated global prevalence statistics from the Parkinson’s Foundation 2025 report; added new diagnostic criteria from the International Parkinson and Movement Disorder Society.

What Is the Current Global Prevalence of Parkinson’s Disease in 2026?

Over 10 million people worldwide are living with Parkinson’s disease as of 2026, according to the Parkinson’s Foundation’s 2025 prevalence report. This figure represents a 15% increase from 2020 estimates, driven by aging populations and improved diagnostic capabilities. The World Health Organization (WHO) 2024 Global Health Estimates rank Parkinson’s as the fastest-growing neurological disorder in terms of disability-adjusted life years (DALYs). Prevalence varies significantly by region, with North America and Western Europe reporting the highest rates due to longer life expectancy and better diagnostic infrastructure. The Global Burden of Disease Study 2023, published in The Lancet Neurology, corroborates these trends, showing a 22% increase in Parkinson’s prevalence in low- and middle-income countries since 2015.

How Many People Have Parkinson’s Disease in the United States in 2026?

Approximately 1 million people in the United States have Parkinson’s disease as of 2026, according to the Parkinson’s Foundation. The Michael J. Fox Foundation for Parkinson’s Research reports that about 60,000 new cases are diagnosed each year. A 2022 study published in npj Parkinson’s Disease by researchers at the University of Pennsylvania estimated that the number of Americans with Parkinson’s could reach 1.2 million by 2030. The Centers for Disease Control and Prevention (CDC) 2023 data shows that Parkinson’s is the 14th leading cause of death in the US, with mortality rates increasing 63% over the past two decades. The Parkinson’s Foundation 2025 report corroborates these projections, noting that the aging Baby Boomer generation is a primary driver of this increase.

What Are the Key Statistics on Parkinson’s Disease by Age and Gender?

Demographic Group	Prevalence Rate	Key Source
People over age 60	1-2% of population	Parkinson’s Foundation, 2025
People over age 80	3-5% of population	National Institute on Aging, 2024
Men vs. Women	Men are 1.5x more likely to develop Parkinson’s	The Lancet Neurology, 2023 meta-analysis
Average age at diagnosis	60 years	Michael J. Fox Foundation, 2025
Early-onset (under 50)	5-10% of all cases	Parkinson’s Foundation, 2025

According to the The Lancet Neurology 2023 global burden of disease study, men have a 1.5 times higher risk of developing Parkinson’s disease compared to women. The National Institute on Aging’s 2024 report confirms that prevalence increases sharply after age 60, with rates reaching 3-5% in people over 80. Early-onset Parkinson’s, defined as diagnosis before age 50, accounts for 5-10% of all cases, according to the Parkinson’s Foundation 2025 data. A 2024 study in Neurology by researchers at the University of Rochester found that the male-to-female ratio is highest in North America (1.6:1) and lowest in Asia (1.2:1), suggesting environmental or genetic factors may influence gender disparities.

What Is the Economic Burden of Parkinson’s Disease in the United States?

The economic burden of Parkinson’s disease in the United States is substantial. According to a 2023 study published in Movement Disorders by researchers at the University of California, San Francisco, the total annual cost of Parkinson’s in the US exceeds $52 billion, including $26 billion in direct medical costs and $26 billion in indirect costs from lost productivity and caregiver expenses. The Michael J. Fox Foundation’s 2024 economic analysis projects these costs could reach $80 billion annually by 2037 as the population ages. Globally, the World Health Organization’s 2024 report estimates Parkinson’s costs exceed $100 billion per year across all countries. A 2025 analysis by the RAND Corporation corroborates these figures, adding that caregiver burden accounts for 40% of total costs, with unpaid family caregivers providing an average of 22 hours of care per week.

What Are the Early Signs and Symptoms of Parkinson’s Disease?

The early signs of Parkinson’s disease include tremors in one hand, stiffness, slow movement (bradykinesia), and impaired balance, according to the National Institute of Neurological Disorders and Stroke (NINDS) 2025 clinical guidelines. Other early symptoms may include loss of smell (anosmia), sleep problems such as REM sleep behavior disorder, and changes in handwriting (micrographia). The Parkinson’s Foundation 2025 symptom checklist notes that non-motor symptoms like depression, anxiety, and constipation often appear years before motor symptoms. A 2024 study in Neurology by researchers at Johns Hopkins University found that loss of smell precedes motor symptoms by an average of 4-6 years. The Michael J. Fox Foundation’s 2025 research update confirms that REM sleep behavior disorder is now recognized as a prodromal marker, with 80% of individuals with this condition developing Parkinson’s or a related disorder within 10 years.

How Is Parkinson’s Disease Diagnosed in 2026?

There is no definitive single test for Parkinson’s disease, according to the International Parkinson and Movement Disorder Society (MDS) 2025 diagnostic criteria. Diagnosis is based on medical history, neurological exams, and sometimes DaTscan (dopamine transporter scan) to rule out other conditions. The MDS 2025 criteria require the presence of bradykinesia plus at least one of: resting tremor, rigidity, or postural instability. A 2023 study in JAMA Neurology by researchers at Harvard Medical School found that DaTscan improves diagnostic accuracy by 15-20% in ambiguous cases. The Michael J. Fox Foundation’s 2025 diagnostic guidelines recommend referral to a movement disorder specialist for confirmation. A 2025 study in The Lancet Digital Health by researchers at the University of Oxford found that smartphone-based gait analysis can detect early Parkinson’s with 87% accuracy, offering a potential screening tool for primary care settings.

What Causes Parkinson’s Disease?

The exact cause of Parkinson’s disease remains unknown, but it involves the progressive loss of dopamine-producing neurons in the substantia nigra region of the brain, according to the National Institute on Aging 2024 fact sheet. Genetics accounts for approximately 10-15% of cases, with mutations in the LRRK2, GBA, and SNCA genes being the most common, according to a 2023 meta-analysis in Nature Reviews Neurology. Environmental factors such as pesticide exposure, head trauma, and well-water consumption have been associated with increased risk, according to the Parkinson’s Foundation 2025 environmental risk report. A 2024 study in Environmental Health Perspectives by researchers at the University of California, Los Angeles found that exposure to the pesticide paraquat increases Parkinson’s risk by 2.5 times. The National Institutes of Health (NIH) 2025 research update corroborates these findings, noting that the interaction between genetic susceptibility (particularly GBA mutations) and environmental triggers is a major focus of current research.

What Are the Current Treatment Options for Parkinson’s Disease in 2026?

Treatment for Parkinson’s disease focuses on managing symptoms, as there is no cure, according to the American Academy of Neurology (AAN) 2025 clinical practice guideline. Levodopa/carbidopa remains the most effective medication, with approximately 75% of patients experiencing significant symptom improvement, according to a 2023 Cochrane review. Deep brain stimulation (DBS) is an effective surgical option for advanced cases, with a 2024 study in The New England Journal of Medicine showing 40% improvement in motor symptoms over 5 years. Newer treatments include focused ultrasound, approved by the FDA in 2024 for tremor-dominant Parkinson’s, and gene therapies currently in clinical trials, according to the Michael J. Fox Foundation 2025 research pipeline report. A 2025 study in Science Translational Medicine by researchers at the University of Pittsburgh found that a new GLP-1 receptor agonist reduced motor symptom progression by 30% over 12 months in a Phase 2 trial, representing a potential disease-modifying therapy.

What Is the Prognosis and Life Expectancy for Parkinson’s Disease?

The prognosis for Parkinson’s disease varies significantly by individual, but most people live 10-20 years after diagnosis, according to the Parkinson’s Foundation 2025 patient guide. A 2024 study in Neurology by researchers at the Mayo Clinic found that the average life expectancy after diagnosis is 14.5 years, with early-onset patients living longer (20+ years) and those diagnosed after age 70 having shorter survival (7-10 years). The Michael J. Fox Foundation’s 2025 research update notes that mortality is primarily driven by complications such as falls, pneumonia, and aspiration, rather than the disease itself. A 2023 study in JAMA Neurology by researchers at the University of Michigan found that regular exercise and physical therapy can extend functional independence by 2-3 years, improving quality of life and reducing fall risk.

How Does Parkinson’s Disease Compare to Other Neurodegenerative Conditions?

Condition	Global Prevalence (2026)	Average Age of Onset	Primary Symptoms	Disease-Modifying Treatment Available
Parkinson’s Disease	10 million	60 years	Tremor, rigidity, bradykinesia	No (symptomatic only)
Alzheimer’s Disease	55 million	65 years	Memory loss, cognitive decline	No (symptomatic only)
Multiple Sclerosis	2.8 million	30 years	Vision loss, fatigue, mobility issues	Yes (DMTs available)
ALS (Lou Gehrig’s)	350,000	55 years	Muscle weakness, paralysis	Yes (limited efficacy)

According to the World Health Organization 2024 Global Health Estimates, Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease, which affects 55 million people worldwide. Unlike multiple sclerosis, which has disease-modifying therapies (DMTs) that can slow progression, Parkinson’s currently has no approved disease-modifying treatment. The Alzheimer’s Association 2025 fact sheet confirms that Alzheimer’s prevalence is 5.5 times higher than Parkinson’s, but Parkinson’s is growing faster in terms of disability-adjusted life years (DALYs), increasing 72% since 2000 compared to 38% for Alzheimer’s.

What Research Breakthroughs Are Expected for Parkinson’s Disease by 2030?

The Michael J. Fox Foundation’s 2025 research pipeline report identifies three major breakthroughs expected by 2030. First, biomarker-based diagnosis using alpha-synuclein seed amplification assays (RT-QuIC) from spinal fluid or skin biopsies, which a 2024 study in The Lancet Neurology by researchers at the University of California, San Diego found has 95% sensitivity for early-stage Parkinson’s. Second, disease-modifying therapies targeting the GBA and LRRK2 genetic pathways, with Phase 3 trials expected to complete by 2027, according to the Parkinson’s Foundation 2025 research update. Third, adaptive deep brain stimulation systems that adjust stimulation in real-time based on brain activity, which a 2025 study in Nature Medicine by researchers at the University of California, San Francisco showed improved motor symptom control by 50% compared to standard DBS. The National Institute of Neurological Disorders and Stroke (NINDS) 2025 strategic plan corroborates these priorities, allocating $300 million annually to Parkinson’s research through 2030.